Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial
| Autor: | Mercedes Palomar, F. Barcenilla, A. Martínez-Pellús, J. Nava, Francisco Álvarez-Lerma, J. Insausti-Ordeñana, A. Torres-Martí, R. Jordá-Marcos, E. Maraví-Poma |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
medicine.medical_specialty Critical Care Penicillanic Acid Ceftazidime Critical Care and Intensive Care Medicine Tazobactam Multicenter trial Internal medicine Intensive care Pneumonia Bacterial polycyclic compounds medicine Humans Hospital Mortality Prospective Studies Hospitals Teaching Amikacin Aged Proportional Hazards Models Piperacillin Cross Infection business.industry Middle Aged Survival Analysis Cephalosporins Surgery Piperacillin Tazobactam Drug Combination Treatment Outcome Tolerability Spain Piperacillin/tazobactam Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Intensive Care Medicine. 27:493-502 |
| ISSN: | 1432-1238 0342-4642 |
| Popis: | Objective: To compare clinical and bacteriological efficacy as well as tolerability of two regimens of broad-spectrum antibiotics (ceftazidime versus piperacillin/tazobactam) combined with amikacin in the treatment of nosocomial pneumonia in intensive care patients. Design: Open label, prospective, multicenter, and randomized phase III clinical trial. Setting: Medical or surgical intensive care units (ICUs) of nine acute-care teaching hospitals in Spain. Patients and participants: One hundred and twenty-four ICU patients with nosocomial pneumonia and requiring mechanical ventilation were included. They were randomized to receive amikacin (15 mg/day divided into two doses) combined with either piperacillin (4 g every 6 h) and tazobactam (0.5 g every 6 h) (n = 88) or ceftazidime (2 g every 8 h) (n = 36). Measurements and results: The causative pathogen was determined in 60.2% of patients in the group of amikacin plus piperacillin/tazobactam and in 76.9% in the group of amikacin plus ceftazidime. A total of 94 bacterial organisms were isolated among which gram-negative bacilli predominated, Pseudomonas aeruginosa being the most frequent. Clinical response at the end of antibiotic therapy was considered satisfactory (cure and/or improvement) in 63.9% of patients in the amikacin plus piperacillin/tazobactam group and in 61.5% in the amikacin plus ceftazidime (odds ratio 1.1; 95% confidence interval 0.44–2.75). Eradication or presumptive eradication rates for each pathogen and for either gram-negative or gram-positive bacteria were similar in both antibiotic combinations (odds ratio 1.2; 95% confidence interval 0.39–3.66). A total of 21 adverse effects (23.9%) occurred in the amikacin plus piperacillin and tazobactam group and six (16.7%) in the amikacin plus ceftazidime group, thrombocytosis, renal dysfunction, and hepatic cytolysis being the most common. The efficacy and tolerability of the two therapeutic regimens were similar not only in the whole study population, but also in the subset of P. aeruginosa-related pneumonia (odds ratio 1; 95% confidence interval 0.08–13.37). Conclusions: Amikacin associated with either ceftazidime or piperacillin and tazobactam has shown comparable efficacy and tolerability in the treatment of ICU patients with nosocomial pneumonia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink